NewAmsterdam Pharma Presents Promising Phase 3 Trial Data

NewAmsterdam Pharma Company ( (NAMS) ) has shared an announcement.

On May 7, 2025, NewAmsterdam Pharma announced additional data from its BROADWAY and TANDEM Phase 3 clinical trials, presented at the European Atherosclerosis Society Congress and published in leading medical journals. The data demonstrated significant reductions in LDL-C levels and improvements in cardiovascular biomarkers with the use of obicetrapib, both as monotherapy and in combination with ezetimibe, highlighting its potential as a foundational therapy in CVD management. The trials showed a 45% reduction in lipoprotein(a) and a 21% reduction in major adverse cardiovascular events, reinforcing obicetrapib’s promise as an effective oral treatment for CVD.

Spark’s Take on NAMS Stock

According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.

NewAmsterdam Pharma’s stock score is impacted by financial challenges typical of biotech firms, such as operational losses and negative cash flow. The strong balance sheet and strategic board appointment offer stability and future growth potential. However, weak technical indicators and valuation metrics underscore caution in the short term.

To see Spark’s full report on NAMS stock, click here.

More about NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), particularly for those for whom existing therapies are not sufficiently effective or well-tolerated.

Average Trading Volume: 994,552

Technical Sentiment Signal: Sell

Current Market Cap: $2.13B

For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.